|0.238 -0.002 (-0.79%)||12-08 15:52|
|Targets||6-month :||0.44||1-year :||0.56|
|Resists||First :||0.38||Second :||0.48|
|Supports||First :||0.21||Second :||0.18|
|MAs||MA(5) :||0.25||MA(20) :||0.32|
|MA(100) :||0.57||MA(250) :||1.51|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||9.9||D(3) :||9.8|
|52-week||High :||8||Low :||0.21|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ATNF ] has closed above bottom band by 12.9%. Bollinger Bands are 21.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||0.25 - 0.25||0.25 - 0.25|
|Low:||0.22 - 0.22||0.22 - 0.22|
|Close:||0.23 - 0.24||0.24 - 0.24|
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||7 (M)|
|Shares Float||7 (M)|
|Held by Insiders||7.4 (%)|
|Held by Institutions||4.1 (%)|
|Shares Short||160 (K)|
|Shares Short P.Month||104 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||-0.02|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-56.2 %|
|Return on Equity (ttm)||-312.1 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-12 (M)|
|Levered Free Cash Flow||-6 (M)|
|Price to Book value||-11.91|
|Price to Sales||0|
|Price to Cash Flow||-0.16|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|